Targets › PRG4
2 programs from 1 company in 2 trials: 2 Phase 2; Ophthalmology, Immunology; next expected readout Dec 2026.
Plays a role in boundary lubrication within articulating joints. Prevents protein deposition onto cartilage from synovial fluid by controlling adhesion-dependent synovial growth and inhibiting the adhesion of synovial cells to the cartilage surface.; FUNCTION: Isoform F plays a role as a growth factor acting on the primitive cells of both hematopoietic and endothelial cell lineages. (UniProt, Q92954)
Open in Phaseline: the race on PRG4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Lubris Bio | rhPRG4 Recombinant human proteoglycan 4 (lubricin) | PRG4 | Phase 2 | Sjögren's Syndrome | Dec 2026 |
| Lubris Bio | rhPRG4 450 μg/ml Recombinant human proteoglycan 4 (lubricin analog) | PRG4 | Phase 2 | Ocular Graft Versus Host Disease | Mar 2027 |
Ocular Graft Versus Host Disease (1) Sjögren's Syndrome (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.